Investment Rating - The report maintains an "Overweight" rating for the defense and military industry [6]. Core Insights - The geopolitical uncertainty, particularly regarding Japan's shift from "strategic ambiguity" to potential military intervention in the Taiwan Strait, has heightened the focus on the military industry [19][20]. - The defense sector is expected to see increased attention and potential investment opportunities due to the evolving geopolitical landscape [11][20]. Market Overview - The defense and military index of Shenwan fell by 1.72% this week, while the Shanghai Composite Index dropped by 3.90% [29]. - The defense and military sector's PE (TTM) stands at 67.3 times, with sub-sectors like aviation equipment at 71.5 times and aerospace equipment at 271.2 times [36]. Key Sector Dynamics Controlled Nuclear Fusion - Shanghai Electric has disclosed its involvement in multiple major fusion projects, including the domestic first plasma burning experiment device BEST and the international ITER project [21]. Low-altitude Economy - The 27th High-Tech Fair's low-altitude economy exhibition in Shenzhen showcased over 200 companies, covering the entire supply chain from eVTOL to drone components [22]. Aviation Engines & Turbines - China Aviation Power showcased 19 types of power products at the Dubai Airshow, marking the first appearance of the C919 in the Middle East [23]. Satellite Internet - The World Internet Conference highlighted the application of satellite internet in enhancing county-level economic development [26]. Suggested Focus Areas - **Missile and Military Electronics**: Companies like Zhenhua Technology, Hongyuan Electronics, and Huada Electronics are recommended for investment [16]. - **Aviation Engines**: Focus on companies like AVIC Engine and AVIC Control [16]. - **Military Trade**: Companies such as AVIC Chengfei, AVIC Shenyang, and AVIC Xi'an are highlighted [16]. - **New Domains and Quality Construction**: Emphasis on commercial aerospace and low-altitude economy companies [16].

Investment Rating - The industry investment rating is "Overweight (Maintain)" [2] Core Insights - The AI comic industry is entering a period of policy benefits, with high-quality content and technology platforms expected to benefit significantly [1][4] - The market for AI comics is experiencing rapid growth, with platforms like Douyin reporting over 400 million daily views for original content [4] - Regulatory changes are expected to accelerate the elimination of low-quality content, creating greater opportunities for high-quality professional creators [4] Summary by Relevant Sections Industry Overview - The total number of listed companies in the industry is 130, with a total market capitalization of 1,771.88 billion yuan and a circulating market capitalization of 1,637.98 billion yuan [2] Key Company Status - Rongxin Culture: Current stock price is 35.39 yuan, with projected EPS improving from -0.53 in 2024 to 0.71 in 2027, maintaining an "Overweight" rating [2] - Zhongwen Online: Current stock price is 28.34 yuan, with projected EPS improving from -0.33 in 2024 to 0.22 in 2027, also rated "Overweight" [2] - Yidian Tianxia: Current stock price is 43.08 yuan, with projected EPS increasing from 0.46 in 2023 to 0.85 in 2027, rated "No Coverage" [2] Market Dynamics - Major platforms are actively expanding their comic business, with iQIYI launching a dedicated comic channel and Tencent testing new comic mini-programs [4] - The introduction of new policies by the National Radio and Television Administration aims to regulate the quality of animated content, which is expected to benefit compliant and aesthetically pleasing creators [4] - The adjustment of revenue-sharing models by ByteDance platforms indicates a shift towards encouraging high-quality content production [4]

Report Summary 1. Report Industry Investment Rating No information about the industry investment rating is provided in the report. 2. Core Viewpoints - Bond - type ETFs had significant net inflows in the past week, with credit - type ETFs leading the way, and large cumulative net inflows throughout the year [3]. - The net values of various bond ETF products recovered significantly in the past week, with some products performing well and others showing different trends [4]. - Credit - bond ETFs and science - innovation bond ETFs had certain increases in unit net value, and their discount rates were at specific levels [5]. 3. Summary by Relevant Catalogs 3.1 Funds Flow - As of November 21, 2025, bond - type ETFs had a total net inflow of 12.729 billion yuan in the past week. Interest - rate, credit, and convertible - bond ETFs had net inflows of 3.538 billion yuan, 6.636 billion yuan, and 2.555 billion yuan respectively. Among credit - type ETFs, short - term financing, corporate bonds, and urban investment bonds had net inflows of 2.598 billion yuan, 1.269 billion yuan, and 1.212 billion yuan respectively, while market - making credit bonds had a net outflow of 252 million yuan, and science - innovation bonds had a net inflow of 1.809 billion yuan. - As of November 21, 2025, the cumulative net inflows of interest - rate, credit, and convertible - bond ETFs for the year were 74.2 billion yuan, 445.363 billion yuan, and 25.137 billion yuan respectively, with a total of 544.7 billion yuan [3]. 3.2 Net Value Performance - Throughout the week, the net values of various bond ETF products recovered significantly. As of November 21, 2025, the 5 - year local - bond ETF and 10 - year local - bond ETF performed well, rising 0.15% and 0.14% respectively. The government - financial bond ETF and 0 - 4 local - bond ETF both rose 6BP. Treasury - bond ETFs and state - development - bond ETFs performed steadily. Convertible - bond ETFs and Shanghai - Stock - Exchange convertible - bond ETFs fell 1.72% and 1.37% respectively last week [4]. 3.3 Performance of Credit - Bond ETFs and Science - Innovation Bond ETFs - As of November 21, 2025, the median unit net values of credit - bond ETFs and science - innovation bond ETFs were 1.0126 and 1.0008 respectively, rising 0.01% and 0.02% throughout the week. Among credit - bond ETFs, Dacheng Credit - Bond ETF performed well, rising 0.04%. Among science - innovation bond ETFs, Fuguo, Boshi, and JingShun Science - Innovation Bond ETFs performed relatively well. As of November 21, 2025, the median discount rate of credit - bond ETFs was 25BP, and that of science - innovation bond ETFs was 22BP [5]. 3.4 Credit - Type ETF Duration Tracking - As of November 21, 2025, the holding durations of short - term financing ETFs, corporate - bond ETFs, and urban - investment - bond ETFs were 0.40 years, 1.84 years, and 2.21 years respectively. Among market - making credit - bond ETFs, the median holding durations of products tracking the Shanghai - market - making corporate - bond and Shenzhen - market - making corporate - bond indexes were 3.789 years and 2.87 years respectively. Among science - innovation bond ETFs, the median holding durations of products tracking the AAA science - innovation bond, Shanghai - AAA science - innovation bond, and Shenzhen - AAA science - innovation bond indexes were 3.47 years, 3.56 years, and 3.24 years respectively [8]. 3.5 Report Abstract - Last week, the ChinaBond New Composite Index rose 0.03% throughout the week. Short - term pure - bond and medium - long - term pure - bond funds rose 0.02% and 0.02% respectively. The ChinaBond AAA Science - Innovation Bond Index and the Shanghai Stock Exchange Benchmark Market - Making Corporate - Bond Index rose 0.03% and 0.03% respectively [7].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [5]. Core Insights - The report emphasizes the importance of seizing opportunities following market corrections, particularly in anticipation of improvements in 2026. It notes that the pharmaceutical sector's fundamentals remain strong despite recent market fluctuations, and it is currently at a valuation bottom. The report suggests focusing on innovative drugs and companies with potential for operational improvements in 2025 [7][11]. Summary by Sections Industry Overview - The pharmaceutical sector consists of 498 listed companies with a total market capitalization of approximately 70,594.11 billion [2]. - The sector has experienced a decline of 6.88% recently, with various sub-sectors such as pharmaceutical commerce and biopharmaceuticals also facing downturns [11]. Market Dynamics - The report highlights a significant market correction, with the Shanghai Composite Index down by 3.77% and the pharmaceutical sector underperforming [11]. - It notes that the overall performance of the pharmaceutical sector has been positive since the beginning of the year, with a return of 13.69%, slightly outperforming the broader market [18]. Investment Opportunities - The report identifies key companies to watch, including: - CDMO leaders: WuXi AppTec, WuXi Biologics, and WuXi AppTec [11]. - Front-end CROs: Tigermed, ProPhase, and Zhaoyan New Drug [11]. - Medical devices: United Imaging Healthcare and HaiTai New Light [11]. - Biopharmaceuticals: I-Mab Biopharma and Hualan Biological Engineering [11]. - It also suggests focusing on companies with innovative drug pipelines and those that are transitioning from biotech to biopharma [11]. Company Performance - The report provides a list of recommended stocks, including: - WuXi AppTec (66.45), rated "Buy" - Three Life Pharmaceuticals (29.34), rated "Buy" - Tigermed (49.59), rated "Buy" - Xiansheng Pharmaceutical (12.85), rated "Buy" - Betta Pharmaceuticals (48.60), rated "Buy" [5][31]. Regulatory and Market Trends - The report discusses recent regulatory developments, including a call from the vaccine industry association to avoid low-cost bidding practices to stabilize profit margins for leading vaccine companies [11][12]. - It also notes significant acquisitions and advancements in drug development, such as Johnson & Johnson's acquisition of Halda Therapeutics for $30.5 billion [11].

Report Overview - Report Name: Credit Business Weekly Report - How to View the Recent Correction in the A-share Technology Sector - Report Date: November 24, 2025 - Analyst: Xu Chi, Zhang Wenyu - Research Institution: Zhongtai Securities Research Institute Report Industry Investment Rating - Not provided in the report Core Viewpoints - The current correction in the A-share technology sector is mainly due to the adjustment of US AI leaders, the year - end defensive strategy of institutional funds, and the decline in trading motivation of leveraged funds during the policy vacuum period. However, the technology market is far from over and is expected to continue after a short - term correction [6][7]. - Mid - term, the A - share market still has upward potential under multiple factors, and investors are advised to make mid - term layouts around four main lines: Hong Kong technology leaders, vertical applications brought by the AI technological revolution, innovative drugs and medical AI, and high - dividend asset allocation [7]. Market Review Market Performance - Last week, most major market indices declined, with the ChiNext Index having the largest decline of - 6.15%, and the Shanghai 50 Index having the smallest decline of - 2.72% [8][9]. - Among the large - scale industry indices, the Telecommunication Services Index and the Daily Consumption Index performed relatively well, with weekly declines of - 1.24% and - 2.28% respectively; the Materials Index and the Healthcare Index performed weakly, with declines of - 7.49% and - 6.79% respectively [8][9]. - Among the 30 Shenwan primary industries, no industry rose. The industries with smaller declines were banks, media, and food and beverage, with declines of 0.89%, 1.25%, and 1.44% respectively; the industries with larger declines were power equipment, basic chemicals, and commercial retail, with declines of 10.54%, 7.47%, and 7.24% respectively [8][14][17]. Trading Heat - The average daily trading volume of the Wind All - A Index last week was 1865.036 billion yuan (previous value: 2043.827 billion yuan), at a relatively high historical level (85.60% of the three - year historical quantile) [8][21]. Valuation Tracking - As of November 21, 2025, the valuation (PE_TTM) of the Wind All - A Index was 21.27, a decrease of - 0.93 from the previous week, at the 86.70% quantile of the past five - year history. None of the 30 Shenwan primary industries saw a valuation (PE_TTM) recovery [8][28]. Market Observation Reasons for the A - share Technology Sector Correction - The adjustment of the A - share technology sector is mainly due to the adjustment of US AI leaders. The high valuation of US AI leaders has led to discussions about the bubble, and the decrease in the expectation of a Fed rate cut in December has increased volatility. The A - share technology sector is affected by the US due to industrial chain correlation and valuation benchmarking [6]. - At the end of the year, institutions usually adopt a defensive strategy to lock in annual returns, which has a greater impact on high - valuation technology sectors such as electronics and communications [6]. - The possibility of intensive policy introduction in the near future is low, which may lead to a decline in the trading motivation of leveraged funds [6]. Outlook for the Technology Market - The technology market is far from over. The probability of a fundamental reversal of the US AI industry is low, and it will still provide a large valuation growth space for A - share comparable companies. The current development stage of the A - share AI sector roughly corresponds to the period from 2023 - 2024 in the US when funds spread from hardware to applications [7]. Capital Flow Analysis - Last week, funds from different channels were still divided, with both withdrawal and bottom - fishing. ETF and northbound funds had a net inflow on a weekly basis, especially on Friday. The departure of major industrial shareholders slowed down, while leveraged funds showed signs of leaving [7]. Investment Recommendations - Mid - term, the A - share market still has upward potential under multiple factors. Investors are advised to make mid - term layouts around four main lines: Hong Kong technology leaders, vertical applications brought by the AI technological revolution, innovative drugs and medical AI, and high - dividend asset allocation, which can be extended to stable - income products such as fixed - income + quantitative products [7].

"反内卷" ：治理逻辑与产业影响 证券研究报告/策略专题报告 2025 年 11 月 23 日 * [10] M. C. 执业证书编号：S0740519080003 Email：xuchi@zts.com.cn 执业证书编号：S0740520120003 Email：zhangwy01@zts.com.cn 3、《利率下行周期中的高股息增强 策略》2025-09-10 2025-11-07 报告摘要 2025-09-12 | 引言： | 4 | | --- | --- | | 一、从政府工作报告到"十五五"规划："反内卷"政策脉络 | 4 | | 二、"反内卷"宏观背景：内需不足导致"价格"压力显现 | 5 | | 三、上一轮"供给侧"政策如何演绎？ | 9 | | 四、本轮"反内卷"政策宏观环境有何不同？ | 12 | | 4.1 宏观环境的根本变化 12 | | | 4.2 产业基础的全新格局 14 | | | 4.3 政策取向的结构性调整 | 15 | | 五、本轮"反内卷"的战略逻辑："扭转通缩"转向"提高产业议价权" 16 | | | 5.1 为何本轮"反内卷"或成为服务于国家竞争力提升的关键抓手？ ...

1. Report Industry Investment Rating - Not provided in the given content 2. Core View of the Report - The equity market has continued its style rotation this week, with technology stocks that rose significantly before the year experiencing continuous adjustments due to year - end profit - taking pressure and overseas market adjustments. The sudden hawkish stance of the Fed, better - than - expected employment data, and the "end - of - the - world options day" of stock index futures have further amplified market volatility. This week, there has been an unusual situation of "double - kill" in both the stock and bond markets, and the possibility of a "double - rise" in the stock and bond markets in December is not high as the bond market faces a shortage of incremental funds [1][2][3][6] 3. Summary of Related Catalogs Equity Market - **Adjustment Factors**: Technology stocks are adjusted due to year - end profit - taking pressure from absolute - return annuities and insurance funds, and the overseas market adjustment caused by concerns about high valuations in the AI sector and the lack of market response to Nvidia's earnings [1] - **Amplifying Factors**: The sudden hawkish stance of the Fed and better - than - expected employment data have made the market pessimistic about the Fed's December interest - rate cut, and the "end - of - the - world options day" of stock index futures has further amplified market volatility [2][3] Bond Market - **Weak Performance**: Since the end of the central bank's bond - buying transactions, the bond market has been in a state of weak oscillation and shrinking trading volume. The daily trading volume of long - term and ultra - long - term bonds has decreased from more than 5,500 transactions in September and October to more than 4,400 transactions in November. The slope of the central bank's short - end bond purchases in November is weaker than that in October [4][17] - **Buying and Selling Forces**: Insurance is the main buyer of long - term bonds, while securities firms are the main sellers. Insurance is pre - heating for the "good start" at the end of the year, and securities firms consider the risk - return ratio of large - exposure unilateral trading before the year - end assessment. Insurance funds have felt an increase in dividend - paying insurance and a weakening of investment in long - duration assets, and banks are more cautious in their investment behavior [4][19] - **Duration**: The fund duration has declined this week, basically erasing the increase from the end of October to early November. Interest - rate bond funds contribute the main decline, while short - end and credit bond funds are relatively stable. As of Friday, the latest reading of the duration of medium - and long - term bond funds is 3.41 years, dropping to the 28% percentile level for the year [5][21] - **Future Outlook**: The possibility of a "double - rise" in the stock and bond markets in December is not high as the bond market faces a shortage of incremental funds, the hedging trading logic lacks sustainable verification in liability behavior, and the trading and allocation difficulties in December have increased [6][24]

Investment Rating - The report assigns a "Buy" rating for the company for the first time [4] Core Views - The global upgrade of disposable hygiene products is transitioning from "internal competition" to "external competition," accelerating the overseas expansion of non-woven fabric manufacturing. The company is positioned to benefit from this trend, with a global supply chain already established [4][39] - The overseas market for absorbent hygiene products is projected to have a market space of approximately $7.16 billion, which is over three times the domestic market size [5][34] Summary by Sections Industry Logic - The upgrade of global absorbent hygiene products is driven by the transition from spunbond non-woven fabrics to hot air non-woven fabrics, benefiting upstream suppliers and indicating a reversal of current challenges [5][9] - Since 2021, cross-border brands have played a pivotal role in reshaping the overseas market landscape, prompting global giants to accelerate product upgrades [5][19] Company Logic - The company is a leading supplier of non-woven fabric for disposable hygiene products, with a strong position in the global supply chain and a focus on high-end products that align with current market demands [39][40] - The company has a competitive edge due to its advanced manufacturing processes and established relationships with major clients, which have been built over more than a decade [49] Financial Forecast and Valuation - Revenue is expected to grow from 14.85 billion yuan in 2024 to 18 billion yuan in 2025, with a year-on-year growth rate of 23%. Net profit is projected to increase significantly from 0.27 billion yuan in 2024 to 0.5 billion yuan in 2025, reflecting a 95% year-on-year growth [4][5] - The company's earnings per share (EPS) is forecasted to rise from 0.08 yuan in 2024 to 0.16 yuan in 2025, indicating strong profitability potential [4][5]

Core Insights - The report emphasizes that perovskite tandem batteries are the inevitable choice for the next phase of photovoltaics due to their superior efficiency compared to traditional silicon-based solutions [7][8] - The efficiency ceiling for tandem batteries is projected to be 44%, with expected mass production efficiency exceeding 35% in the long term [8] - Major manufacturers in the perovskite sector have successfully transitioned to large-scale production, with significant efficiency improvements observed in large-area perovskite batteries [8][9] Industry Overview - The report discusses the limitations of single-material solar cells in efficiently utilizing the entire solar spectrum, which tandem batteries aim to address [8] - The commercial viability of perovskite tandem components is highlighted, with a significant price-performance advantage over traditional silicon components, projected to yield a premium of 1.28 CNY/W while maintaining a cost of only 1.2 CNY/W [8] - The anticipated efficiency of tandem components is expected to reach 28% by 2026, with a breakthrough of over 30% deemed inevitable [8] Market Dynamics - The report notes that the perovskite industry has seen a surge in production capacity, with nearly 10 companies operating 100MW lines as of October 2025, and several major players like BOE and CATL investing in GW-level production lines [9] - The compatibility of perovskite tandem technology with existing silicon production capabilities is expected to facilitate further expansion in the industry [9] - Key materials and equipment suppliers are identified, including TCO glass manufacturers like Jinjing Technology and Yaopi Glass, and equipment providers such as Jiejia Weichuang and Jing Shan Light Machinery [9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][11] Core Views - The company has shown resilience in its external sales, with a notable recovery in overseas markets, while domestic sales are expected to stabilize [8] - The company's revenue for FY26H1 was HKD 8.045 billion, a year-on-year decrease of 3.1%, but the decline has narrowed significantly compared to previous periods [7] - The gross profit margin improved by 0.9 percentage points to 40.4%, benefiting from cost control and operational efficiency [7][8] Revenue and Profitability - The company's revenue forecast for the upcoming years is as follows: - 2024A: HKD 18.411 billion - 2025A: HKD 16.903 billion - 2026E: HKD 16.953 billion - 2027E: HKD 17.631 billion - 2028E: HKD 18.513 billion - The year-on-year growth rates for revenue are projected to be -8% for 2025A, 0% for 2026E, 4% for 2027E, and 5% for 2028E [2] - The net profit attributable to the parent company is forecasted as follows: - 2024A: HKD 2.302 billion - 2025A: HKD 2.063 billion - 2026E: HKD 2.193 billion - 2027E: HKD 2.321 billion - 2028E: HKD 2.433 billion - The year-on-year growth rates for net profit are projected to be -10% for 2025A, 6% for 2026E, 6% for 2027E, and 5% for 2028E [2] Market Performance - Domestic sales in the Chinese market for FY26H1 were HKD 4.203 billion, a year-on-year decrease of 6.5%, but the decline has significantly narrowed compared to FY25H2 [7] - Online sales showed strong performance with a year-on-year increase of 13.6%, while offline sales decreased by 12.3% [7] - The North American market revenue for FY26H1 was HKD 2.161 billion, a slight increase of 0.3%, demonstrating strong resilience amid rising international trade barriers [5] - Revenue from Europe and other markets for FY26H1 was HKD 0.765 billion, a year-on-year increase of 4.3% [5] Cost and Margin Analysis - The overall gross profit margin increased to 40.4%, benefiting from a decrease in average unit costs of key raw materials such as leather, chemicals, and steel [8] - However, the company faced increased tariff costs for exports to the United States, which rose from HKD 6.65 million to HKD 78.83 million year-on-year [8]